《新股消息》科济药业递主板上市申请 传计划筹3亿美元
内地临床阶段的生物制药公司科济药业已递交主板上市申请,联席保荐人为高盛及瑞银,据路透旗下IFR引述消息指,公司计划筹3亿美元。
目前,科济药业并无获批准商业化销售的产品及尚未从产品销售产生任何收益,而去年度其经营亏损为3.27亿元人民币,几乎全部经营亏损都是由研发开支及行政开支所致,预期在至少未来几年会产生重大开支及经营亏损,因为公司需要进一步进行临床前研究与开发、继续进行候选产品的临床开发、就候选产品寻求监管批准、对管线产品进行商业化以及增聘必要人员以经营其业务。(el/u) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.